Blood Cancer Journal - Table of Contents alert Volume 6 July 2016

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 6, July 2016 In this issue Reviews Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders. Explore the benefits of submitting your next research article. Reviews Top ‘Acute myeloid leukemia: a comprehensive review and 2016 update’ I De Kouchkovsky and M Abdul-Hay Blood Cancer J 2016 6: e441; 10.1038/bcj.2016.50 Abstract | Full Text New investigational drugs with single-agent activity in multiple myeloma A M Rajan and S Kumar Blood Cancer J 2016 6: e451; 10.1038/bcj.2016.53 Abstract | Full Text Original Articles Top Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome C Y Cher, G M K Leung, C H Au, T L Chan, E S K Ma, J P Y Sim, H Gill, A K W Lie, R Liang, K F Wong, L L P Siu, C S P Tsui, C C So, H W W Wong, S F Yip, H K K Lee, H S Y Liu, J S M Lau, T H Luk, C K Lau, S Y Lin, Y L Kwong and A Y H Leung on behalf of the Hong Kong AML Study Group Blood Cancer J 2016 6: e442; 10.1038/bcj.2016.51 Abstract | Full Text Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke, S Thanendrarajan, J Sawyer, D Alapat, E Tian, C Stein, R Khan, C J Heuck, N Petty, D Avery, D Steward, R Smith, C Bailey, J Epstein, S Yaccoby, A Hoering, J Crowley, G Morgan, B Barlogie and F van Rhee Blood Cancer J 2016 6: e453; 10.1038/bcj.2016.64 Abstract | Full Text Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia S Kayser, A Benner, C Thiede, U Martens, J Huber, P Stadtherr, J W G Janssen, C Röllig, M J Uppenkamp, T Bochtler, U Hegenbart, G Ehninger, A D Ho, P Dreger and A Krämer Blood Cancer J 2016 6: e449; 10.1038/bcj.2016.46 Abstract | Full Text Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma P Ravi, S Kumar, J T Larsen, W Gonsalves, F Buadi, M Q Lacy, R Go, A Dispenzieri, P Kapoor, J A Lust, D Dingli, Y Lin, S J Russell, N Leung, M A Gertz, R A Kyle, P L Bergsagel and S V Rajkumar Blood Cancer J 2016 6: e454; 10.1038/bcj.2016.65 Abstract | Full Text Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells K K Starheim, T Holien, K Misund, I Johansson, K A Baranowska, A-M Sponaas, H Hella, G Buene, A Waage, A Sundan and G Bjørkøy Blood Cancer J 2016 6: e446; 10.1038/bcj.2016.56 Abstract | Full Text First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation M Wilhelm, M Smetak, P Reimer, E Geissinger, T Ruediger, B Metzner, N Schmitz, A Engert, K Schaefer-Eckart and J Birkmann Blood Cancer J 2016 6: e452; 10.1038/bcj.2016.63 Abstract | Full Text Letters to the Editor Top Thrombotic microangiopathy during carfilzomib use: case series in Singapore Y Chen, M Ooi, S F Lim, A Lin, J Lee, C Nagarajan, C Phipps, Y S Lee, N F Grigoropoulos, Z Lao, S Surendran, E M Teh, Y T Goh, W J Chng and S K Gopalakrishnan Blood Cancer J 2016 6: e450; 10.1038/bcj.2016.62 Full Text An open-label phase I dose-finding study of APR-246 in hematological malignancies S Deneberg, H Cherif, V Lazarevic, P-O Andersson, M von Euler, G Juliusson and S Lehmann Blood Cancer J 2016 6: e447; 10.1038/bcj.2016.60 Full Text Allogeneic hematopoietic cell transplantation in patients 70 years: which patients may benefit? S P Haen, M Pham, C Faul, D Dörfel, W Vogel, L Kanz and W A Bethge Blood Cancer J 2016 6: e443; 10.1038/bcj.2016.54 Full Text Search for familial clustering of cancer in monoclonal gammopathy of unknown significance K Hemminki, A Försti, J Sundquist and X Li Blood Cancer J 2016 6: e445; 10.1038/bcj.2016.58 Full Text Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL B Heyman, A D Volkheimer and J B Weinberg Blood Cancer J 2016 6: e440; 10.1038/bcj.2016.49 Full Text Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen S J Jacobus, S V Rajkumar, M Weiss, A K Stewart, E A Stadtmauer, N S Callander, L M Dreosti, M Q Lacy and R Fonseca Blood Cancer J 2016 6: e448; 10.1038/bcj.2016.55 Full Text Reprogramming of Notch1-induced acute lymphoblastic leukemia cells into pluripotent stem cells in mice H Zhang, H Cheng, Y Wang, Y Zheng, Y Liu, K Liu, J Xu, S Hao, W Yuan, T Zhao and T Cheng Blood Cancer J 2016 6: e444; 10.1038/bcj.2016.57 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.